Identification

Name
Midazolam
Accession Number
DB00683  (APRD00680)
Type
Small Molecule
Groups
Approved, Illicit
Description

A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. [PubChem] Midazolam is a schedule IV drug in the United States.

Structure
Thumb
Synonyms
  • Buccolam
  • Dormicum
  • Midazolam
  • Midazolamum
External IDs
Dea No. 2884 / Ro 21-3981/001 / Ro 21-3981/003
Product Ingredients
IngredientUNIICASInChI Key
Midazolam HydrochlorideW7TTW573JJ59467-96-8PLYSCVSCYOQVRP-UHFFFAOYSA-N
Midazolam maleate77520S18SE59467-94-6XYGVIBXOJOOCFR-BTJKTKAUSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BuccolamSolution2.5 mgBuccalShire Services Bvba2011-09-05Not applicableEu
BuccolamSolution10 mgBuccalShire Services Bvba2011-09-05Not applicableEu
BuccolamSolution5 mgBuccalShire Services Bvba2011-09-05Not applicableEu
BuccolamSolution7.5 mgBuccalShire Services Bvba2011-09-05Not applicableEu
Midazolam InjectionSolution1 mgIntramuscular; IntravenousNovopharm Limited2001-12-17Not applicableCanada
Midazolam InjectionSolution1 mgIntramuscular; IntravenousSandoz Canada Incorporated1999-07-21Not applicableCanada
Midazolam InjectionSolution1 mgIntramuscular; IntravenousFresenius Kabi2001-03-26Not applicableCanada
Midazolam InjectionSolution5 mgIntramuscular; IntravenousNovopharm Limited2001-12-17Not applicableCanada
Midazolam InjectionSolution5 mgIntramuscular; IntravenousSandoz Canada Incorporated1999-07-21Not applicableCanada
Midazolam InjectionSolution1 mgIntramuscular; IntravenousPfizer2015-03-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-midazolam Injectable 1 mg/mlLiquid1 mgIntramuscular; IntravenousApotex Corporation2001-04-102013-08-02Canada
Apo-midazolam Injectable 5 mg/mlLiquid5 mgIntramuscular; IntravenousApotex Corporation2001-04-102013-08-02Canada
MidazolamInjection, solution5 mg/mLIntramuscular; IntravenousThe Medicines Company2000-07-14Not applicableUs
MidazolamInjection, solution1 mg/mLIntramuscular; IntravenousSagent Pharmaceuticals2012-03-19Not applicableUs
MidazolamInjection1 mg/mLIntramuscular; IntravenousCardinal Health2000-06-20Not applicableUs
MidazolamInjection, solution1 mg/mLIntramuscular; IntravenousAPP Pharmaceuticals, Inc.2000-07-14Not applicableUs
MidazolamInjection5 mg/mLIntramuscular; IntravenousAkorn2005-05-06Not applicableUs
MidazolamInjection1 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical2000-06-20Not applicableUs
MidazolamInjection5 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical2000-06-20Not applicableUs
MidazolamInjection, solution5 mg/mLIntramuscular; IntravenousSagent Pharmaceuticals2012-03-19Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Midazolam HClInjection, solution.5 mg/mLIntravenousCantrell Drug Company2013-01-30Not applicableUs
Midazolam HClInjection, solution1 mg/mLIntravenousCantrell Drug Company2010-08-02Not applicableUs
International/Other Brands
Anquil (General Pharma) / Benzosed (Pharmaceutical) / Dalam (Richmond) / Damizol (Specifar) / Demizolam (Dem Ilaç) / Doricum (Roche) / Dormicum (Roche) / Dormid (Scott) / Dormipron (Chalver) / Dormire (Cristália) / Dormitol (Square) / Dormixal (Demo) / Dormonid (Roche) / Drimnorth (Northia) / Epistatus (IFET) / Flormidal (Galenika) / Fulsed (Ranbaxy) / Fulsed Injection (Terapia) / Garen (Bio-Pharma) / Gobbizolam (Gobbi) / Hipnazolam (EMS) / Hipnoz (Pharos) / Hypnofast (Incepta) / Hypnovel (Roche) / Ipnovel (Roche) / Nocturna (Lafi) / Setam (Rimsa) / Talentum (Fisiopharma) / Terap (Sanitas) / Versed (Roche)
Categories
UNII
R60L0SM5BC
CAS number
59467-70-8
Weight
Average: 325.767
Monoisotopic: 325.078203343
Chemical Formula
C18H13ClFN3
InChI Key
DDLIGBOFAVUZHB-UHFFFAOYSA-N
InChI
InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3
IUPAC Name
12-chloro-9-(2-fluorophenyl)-3-methyl-2,4,8-triazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaene
SMILES
CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12

Pharmacology

Indication

The midazolam injection is indicated for preoperative sedation/anziolysis/amnesia. It is also an agent for sedation/anziolysis/amnesia prior to or during diagnostic, therapeutic, or endoscopic procedures. Midazolam can also be given intravenously for induction of general anaesthesia.

Structured Indications
Pharmacodynamics

Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmacodynamic properties of midazolam and its metabolites, which are similar to those of other benzodiazepines, include sedative, anxiolytic, amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to result from reversible interactions with the (gamma)-amino butyric acid (GABA) benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the central nervous system. The action of midazolam is readily reversed by the benzodiazepine receptor antagonist, flumazenil.

Mechanism of action

It is thought that the actions of benzodiazepines such as midazolam are mediated through the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which is one of the major inhibitory neurotransmitters in the brain. Benzodiazepines increase the activity of GABA, thereby producing a calming effect, relaxing skeletal muscles, and inducing sleep. Benzodiazepines bind to the benzodiazepine site on GABA-A receptors, which potentiates the effects of GABA by increasing the frequency of chloride channel opening.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-4
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-5
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-6
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit delta
potentiator
Human
AGamma-aminobutyric acid receptor subunit epsilon
potentiator
Human
AGamma-aminobutyric acid receptor subunit pi
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit theta
potentiator
Human
Absorption

Rapidly absorbed after oral administration. The absolute bioavailability of the midazolam syrup in pediatric patients is about 36%. The absolute bioavailability, if given intramuscularly (IM), is greater than 90%. Cmax, IM = 90 ng/mL; Tmax, IM = 0.5 hours. Following IM administered, Cmax for midazolam and its 1-hydroxy metabolite were approxiately one-half of those achieved after intravenous injection.

Volume of distribution
  • 1.24 to 2.02 L/kg [pediatric patients (6 months to <16 years) receiving 0.15 mg/kg IV midazolam,]
  • 1 to 3.1 L/kg [intravenously administered, healthy adults] Female gender, old age, and obesity may increase the volume of distribution. Midazolam may also cross the placenta and has been detected in human milk and cerebrospinal fluid.
Protein binding

97% protein bound.

Metabolism

Midazolam is primarily metabolized in the liver and gut by human cytochrome P450 IIIA4 (CYP3A4) to its pharmacologic active metabolite, (alpha)-hydroxymidazolam (also known as 1-hydroxy-midazolam), and 4-hydroxymidazolam (makes up 5% or less of the biotransformation products). 1-hydroxy-midazolam is at least as potent as the parent compound and may contributed to the overall activity of midazolam. In vitro studies have demonstrated that the affinities of 1- and 4-hydroxy-midazolam for the benzodiazepine receptor are approximately 20% and 7%, respectively, relative to midazolam. It also undergoes N-glucuronidation via UGT1A4.

Route of elimination

Midazolam is primarily metabolized in the liver and gut by human cytochrome P450 IIIA4 (CYP3A4) to its pharmacologic active metabolite, α-hydroxymidazolam, followed by glucuronidation of the α–hydroxyl metabolite which is present in unconjugated and conjugated forms in human plasma. The α- hydroxymidazolam glucuronide is then excreted in urine. No significant amount of parent drug or metabolites is extractable from urine before beta-glucuronidase and sulfatase deconjugation, indicating that the urinary metabolites are excreted mainly as conjugates. The amount of midazolam excreted unchanged in the urine when given intravenously is less than 0.5%. 45% to 57% of the dose was excreted in the urine as 1-hydroxymethyl midazolam conjugate.

Half life

Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)

Clearance
  • 9.3 to 11 mL/min/kg [pediatric patients (6 months to <16 years old)]
  • 0.25 to 0.54 L/hr/kg [intravenous, healthy adults]
Toxicity

LD50=825 mg/kg (Orally in rats). Signs of overdose include sedation, somnolence, confusion, impaired coordination, diminished reflexes, coma, and deleterious effects on vital signs.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Midazolam can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Midazolam can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Midazolam can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Midazolam is combined with 7-Nitroindazole.Experimental
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Midazolam.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Midazolam.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Midazolam.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Midazolam is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Midazolam.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Midazolam is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Midazolam is combined with Alaproclate.Experimental
AlbendazoleThe serum concentration of Midazolam can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Midazolam can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Midazolam can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Alfaxalone.Vet Approved
AlfentanilThe serum concentration of Midazolam can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Midazolam.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Allopregnanolone.Investigational
AlogliptinThe serum concentration of Midazolam can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Midazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Midazolam is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Midazolam is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Midazolam.Approved, Illicit, Investigational
AmantadineThe serum concentration of Midazolam can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Midazolam.Approved, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Midazolam can be decreased when used in combination with Ambroxol acefyllinate.Experimental
Aminohippuric acidThe serum concentration of Midazolam can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe therapeutic efficacy of Midazolam can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Midazolam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Midazolam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Midazolam.Approved
AmlodipineThe serum concentration of Midazolam can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Midazolam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Midazolam is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Midazolam can be increased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Midazolam can be increased when it is combined with Amsacrine.Approved
Antithrombin III humanThe serum concentration of Midazolam can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Midazolam can be increased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Midazolam can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Midazolam can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe serum concentration of Midazolam can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Midazolam is combined with Aripiprazole.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Midazolam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Midazolam is combined with Asenapine.Approved
AstemizoleThe serum concentration of Midazolam can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Midazolam can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Midazolam can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Midazolam.Approved
AtomoxetineThe metabolism of Midazolam can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Midazolam can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Midazolam.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Azaperone.Vet Approved
AzelastineMidazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe serum concentration of Midazolam can be increased when it is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Midazolam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Barbital.Illicit
BatimastatThe serum concentration of Midazolam can be increased when it is combined with Batimastat.Experimental
BelinostatThe serum concentration of Belinostat can be decreased when it is combined with Midazolam.Approved, Investigational
BenazeprilThe serum concentration of Midazolam can be increased when it is combined with Benazepril.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Midazolam is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Midazolam can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe serum concentration of Midazolam can be increased when it is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Midazolam is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Midazolam can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Midazolam.Approved, Vet Approved
BiperidenThe serum concentration of Midazolam can be increased when it is combined with Biperiden.Approved
BivalirudinThe serum concentration of Midazolam can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Midazolam can be increased when it is combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Midazolam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Midazolam can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Midazolam.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Midazolam.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Midazolam is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Midazolam is combined with Bromisoval.Experimental
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Midazolam.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Midazolam is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Midazolam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Bupivacaine.Approved, Investigational
BuprenorphineMidazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Midazolam can be increased when it is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Midazolam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Midazolam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Midazolam is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Midazolam.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Midazolam.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Midazolam.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Midazolam.Approved
CamostatThe serum concentration of Midazolam can be increased when it is combined with Camostat.Experimental
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Midazolam.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Midazolam.Approved
Candesartan cilexetilThe serum concentration of Midazolam can be increased when it is combined with Candesartan.Approved
CandoxatrilThe serum concentration of Midazolam can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Midazolam can be increased when it is combined with Candoxatrilat.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Midazolam is combined with Canertinib.Investigational
CaptoprilThe serum concentration of Midazolam can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Midazolam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Carbinoxamine.Approved
CarbomycinThe serum concentration of Midazolam can be increased when it is combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Midazolam is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Midazolam.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Midazolam is combined with Carisoprodol.Approved
CarvedilolThe serum concentration of Midazolam can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Midazolam can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Midazolam can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Midazolam.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Midazolam is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Midazolam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Midazolam can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlorphenamine.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Midazolam.Approved, Vet Approved
ChlorpropamideThe serum concentration of Midazolam can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Midazolam can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlorzoxazone.Approved
CholesterolThe serum concentration of Midazolam can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Midazolam can be decreased when it is combined with Cholic Acid.Approved
ChymostatinThe serum concentration of Midazolam can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Midazolam can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Midazolam can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Midazolam can be decreased when it is combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Midazolam.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Midazolam.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Midazolam.Approved
ClarithromycinThe serum concentration of Midazolam can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Midazolam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Midazolam is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Midazolam.Approved, Illicit
ClofazimineThe serum concentration of Midazolam can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Midazolam is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Midazolam.Approved, Investigational
ClomipramineThe serum concentration of Midazolam can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Midazolam.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Midazolam is combined with Clopenthixol.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Midazolam.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Midazolam.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Midazolam is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Midazolam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Midazolam is combined with Clozapine.Approved
CobicistatThe serum concentration of Midazolam can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Midazolam.Approved
CocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Midazolam.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Midazolam.Approved
ColforsinThe serum concentration of Midazolam can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Midazolam can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Midazolam.Approved
CopanlisibThe serum concentration of Copanlisib can be decreased when it is combined with Midazolam.Approved
CrizotinibThe metabolism of Midazolam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyclobenzaprine.Approved
CyclophosphamideThe serum concentration of Midazolam can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Midazolam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Midazolam.Approved
DabrafenibThe serum concentration of Midazolam can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Midazolam can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Midazolam.Approved
DantroleneThe risk or severity of adverse effects can be increased when Midazolam is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Midazolam.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Midazolam is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dapoxetine.Investigational
DarexabanThe serum concentration of Midazolam can be increased when it is combined with Darexaban.Investigational
DarunavirThe serum concentration of Midazolam can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Midazolam can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Midazolam.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Midazolam.Approved
DeferasiroxThe serum concentration of Midazolam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Midazolam can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Midazolam can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Midazolam can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Midazolam is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Desflurane.Approved
DesipramineThe serum concentration of Midazolam can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Midazolam can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Midazolam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Midazolam can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe serum concentration of Midazolam can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Midazolam is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Midazolam is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Midazolam.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Midazolam can be increased when it is combined with Diclofenac.Approved, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Midazolam is combined with Diethyl ether.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Midazolam.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Midazolam is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Midazolam.Approved
DigoxinThe serum concentration of Midazolam can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydrocodeine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Midazolam.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Midazolam.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Midazolam.Experimental
DihydroergotamineThe metabolism of Midazolam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Midazolam.Illicit
DiltiazemThe metabolism of Midazolam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Midazolam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Midazolam is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Midazolam is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Midazolam.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dixyrazine.Experimental
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Midazolam.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Midazolam.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Midazolam is combined with Doramectin.Vet Approved
DoxazosinThe serum concentration of Midazolam can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Midazolam can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Midazolam.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Midazolam.Approved, Investigational
DoxycyclineThe metabolism of Midazolam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Midazolam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
DronedaroneThe metabolism of Midazolam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Midazolam is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Midazolam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dyclonine.Approved
DyphyllineThe therapeutic efficacy of Midazolam can be decreased when used in combination with Dyphylline.Approved
EcabetThe serum concentration of Midazolam can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Midazolam is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Midazolam is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Midazolam can be increased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Midazolam.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Midazolam.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Eltanolone.Investigational
EnalaprilThe serum concentration of Midazolam can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Midazolam can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Midazolam can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Midazolam.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Midazolam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Midazolam can be decreased when it is combined with Enzalutamide.Approved
Epigallocatechin GallateThe serum concentration of Midazolam can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Midazolam.Approved, Investigational
ErgonovineThe serum concentration of Midazolam can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Midazolam can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Midazolam.Approved, Investigational
ErythromycinThe serum concentration of Midazolam can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Midazolam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Midazolam.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Midazolam can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Midazolam.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Midazolam.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Midazolam.Approved
EthanolMidazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Midazolam.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Midazolam is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Midazolam is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Etoperidone.Withdrawn
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Midazolam.Approved
EtorphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Midazolam can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Midazolam.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Midazolam.Approved
EzogabineThe risk or severity of adverse effects can be increased when Midazolam is combined with Ezogabine.Approved
FaldaprevirThe serum concentration of Midazolam can be increased when it is combined with Faldaprevir.Investigational
FelbamateThe risk or severity of adverse effects can be increased when Midazolam is combined with Felbamate.Approved
FelodipineThe serum concentration of Midazolam can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe serum concentration of Midazolam can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Midazolam.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Midazolam.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Midazolam.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Midazolam is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Midazolam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe serum concentration of Midazolam can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Midazolam can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Midazolam can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Midazolam can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Midazolam.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Midazolam.Approved
FluvoxamineThe metabolism of Midazolam can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Midazolam can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Midazolam can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Midazolam can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Midazolam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Midazolam is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Midazolam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Midazolam is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Midazolam is combined with Gabapentin Enacarbil.Approved
GabexateThe serum concentration of Midazolam can be increased when it is combined with Gabexate.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Midazolam is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Midazolam.Approved, Investigational
GeldanamycinThe serum concentration of Midazolam can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Midazolam.Approved
GenisteinThe serum concentration of Midazolam can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Midazolam is combined with Gepirone.Investigational
Ginkgo bilobaThe serum concentration of Midazolam can be decreased when it is combined with Ginkgo biloba.Approved, Nutraceutical
GlecaprevirThe serum concentration of Glecaprevir can be decreased when it is combined with Midazolam.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Midazolam is combined with Glutethimide.Approved, Illicit
GlyburideThe serum concentration of Midazolam can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Midazolam can be increased when it is combined with Glycerin.Approved, Investigational
GM6001The serum concentration of Midazolam can be increased when it is combined with GM6001.Experimental
Gramicidin DThe serum concentration of Midazolam can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Midazolam.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Midazolam.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Midazolam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Midazolam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Midazolam is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Midazolam is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Midazolam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneMidazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Midazolam.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Midazolam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Midazolam.Approved
IdelalisibThe serum concentration of Midazolam can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Midazolam can be increased when it is combined with Idraparinux.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Iloperidone.Approved
ImatinibThe metabolism of Midazolam can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Midazolam can be increased when it is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Midazolam.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Midazolam.Approved
IndalpineThe risk or severity of adverse effects can be increased when Midazolam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Midazolam can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Midazolam is combined with Indiplon.Investigational
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Midazolam.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Midazolam.Approved
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Midazolam.Approved, Investigational
IsavuconazoniumThe metabolism of Midazolam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Isoflurane.Approved, Vet Approved
IsoflurophateThe serum concentration of Midazolam can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsradipineThe metabolism of Midazolam can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Midazolam can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Midazolam can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Midazolam.Approved, Vet Approved
IxazomibThe serum concentration of Midazolam can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Midazolam can be increased when it is combined with Josamycin.Approved
KetamineThe serum concentration of Midazolam can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Midazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Midazolam can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Midazolam can be increased when it is combined with Kitasamycin.Experimental
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Midazolam.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Midazolam.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Midazolam.Approved, Investigational
LapatinibThe serum concentration of Midazolam can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Midazolam.Approved
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Midazolam.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Midazolam.Approved
LepirudinThe serum concentration of Midazolam can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Midazolam can be increased when it is combined with Letaxaban.Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Midazolam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Midazolam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Midazolam is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Midazolam.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Midazolam is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Midazolam.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Midazolam is combined with Levorphanol.Approved
LevothyroxineThe serum concentration of Midazolam can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Midazolam can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Midazolam.Approved
LiothyronineThe serum concentration of Midazolam can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Midazolam can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Midazolam can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Midazolam.Approved
LithiumThe risk or severity of adverse effects can be increased when Midazolam is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Midazolam is combined with Lofentanil.Illicit
LomitapideThe serum concentration of Midazolam can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Midazolam.Approved
LopinavirThe serum concentration of Midazolam can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Loprazolam.Experimental
LoratadineThe serum concentration of Midazolam can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Midazolam.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Lormetazepam.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Midazolam.Approved
LovastatinThe metabolism of Midazolam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Midazolam.Approved
LuliconazoleThe serum concentration of Midazolam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Midazolam can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Lurasidone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Midazolam.Illicit, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Midazolam.Approved, Investigational
MaprotilineThe serum concentration of Midazolam can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Midazolam can be increased when it is combined with Mebendazole.Approved, Vet Approved
MebicarThe risk or severity of adverse effects can be increased when Midazolam is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Midazolam can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Midazolam can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelagatranThe serum concentration of Midazolam can be increased when it is combined with Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Midazolam is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe serum concentration of Midazolam can be increased when it is combined with Meprobamate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Midazolam is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Midazolam.Experimental
MethadoneMidazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Midazolam is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Midazolam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Midazolam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Midazolam.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Midazolam.Approved
MethotrimeprazineMidazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Midazolam is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Midazolam is combined with Methylecgonine.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Midazolam.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Midazolam.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Midazolam.Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Midazolam.Approved, Investigational
MetyrosineMidazolam may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Midazolam.Experimental
MibefradilThe serum concentration of Midazolam can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Midazolam can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Midazolam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Midazolam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Midazolam.Approved
MirtazapineMidazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitomycinThe serum concentration of Midazolam can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Midazolam can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Midazolam.Approved, Investigational
MoexiprilThe serum concentration of Midazolam can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Midazolam.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Midazolam.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Midazolam can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Midazolam.Approved
NafamostatThe serum concentration of Midazolam can be increased when it is combined with Nafamostat.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Midazolam.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Midazolam.Approved, Vet Approved
NaltrexoneThe serum concentration of Midazolam can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Midazolam can be increased when it is combined with Naringenin.Experimental
NefazodoneThe metabolism of Midazolam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Midazolam can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Midazolam can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Midazolam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Midazolam can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Midazolam.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Midazolam.Approved
NifedipineThe serum concentration of Midazolam can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Midazolam can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Midazolam.Approved
NisoldipineThe serum concentration of Midazolam can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Midazolam can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Midazolam can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe serum concentration of Midazolam can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Midazolam is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Midazolam.Approved
NorethisteroneThe serum concentration of Midazolam can be decreased when it is combined with Norethisterone.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Midazolam is combined with Nortriptyline.Approved
OdanacatibThe serum concentration of Odanacatib can be decreased when it is combined with Midazolam.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Midazolam.Approved, Investigational
OlaparibThe metabolism of Midazolam can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Midazolam can be increased when it is combined with Oleandomycin.Vet Approved
OlopatadineThe risk or severity of adverse effects can be increased when Midazolam is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Midazolam can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Midazolam.Approved
OmeprazoleThe serum concentration of Midazolam can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Midazolam is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Midazolam is combined with Opium.Approved, Illicit
OrphenadrineMidazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Midazolam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Midazolam can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Midazolam can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Midazolam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxymorphone.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Midazolam can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Midazolam.Approved, Vet Approved
PalbociclibThe serum concentration of Midazolam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Paliperidone.Approved
Palmitic AcidThe serum concentration of Midazolam can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Midazolam.Approved, Investigational
PantoprazoleThe serum concentration of Midazolam can be increased when it is combined with Pantoprazole.Approved
ParaldehydeMidazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe serum concentration of Midazolam can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Midazolam.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Midazolam is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Midazolam.Approved, Vet Approved
PentobarbitalThe metabolism of Midazolam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved
PerazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Perazine.Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Midazolam.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Midazolam can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Midazolam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Midazolam.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Midazolam is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Midazolam is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Midazolam can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Midazolam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Midazolam.Approved, Vet Approved
PhosphoramidonThe serum concentration of Midazolam can be increased when it is combined with Phosphoramidon.Experimental
PibrentasvirThe serum concentration of Pibrentasvir can be decreased when it is combined with Midazolam.Approved
PimozideThe serum concentration of Midazolam can be increased when it is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Midazolam is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Midazolam.Approved
PizotifenThe risk or severity of adverse effects can be increased when Midazolam is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Midazolam can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Midazolam.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Midazolam.Approved
PosaconazoleThe metabolism of Midazolam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleMidazolam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Midazolam.Approved
PrazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Midazolam.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Midazolam.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Midazolam.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Midazolam.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Prilocaine.Approved
PrimidoneThe metabolism of Midazolam can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Midazolam can be increased when it is combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Midazolam can be increased when it is combined with Probenecid.Approved
ProcaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Midazolam.Approved, Vet Approved
ProgesteroneThe serum concentration of Midazolam can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Midazolam.Approved, Vet Approved
PromethazineThe serum concentration of Midazolam can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Midazolam can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Midazolam is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Proparacaine.Approved, Vet Approved
PropofolThe serum concentration of Propofol can be increased when it is combined with Midazolam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Midazolam.Approved, Investigational
ProtriptylineThe serum concentration of Midazolam can be increased when it is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Midazolam is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Midazolam.Approved
PSD502The risk or severity of adverse effects can be increased when Midazolam is combined with PSD502.Investigational
QuazepamThe serum concentration of Midazolam can be increased when it is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Midazolam can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Midazolam.Approved
QuinacrineThe serum concentration of Midazolam can be increased when it is combined with Quinacrine.Approved
QuinaprilThe serum concentration of Midazolam can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Midazolam.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Midazolam.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Quinisocaine.Experimental
RacecadotrilThe serum concentration of Midazolam can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Midazolam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Midazolam is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Midazolam can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Midazolam.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Midazolam.Approved, Investigational
ReboxetineThe serum concentration of Midazolam can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Midazolam can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Midazolam is combined with Remifentanil.Approved
RemikirenThe serum concentration of Midazolam can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Midazolam is combined with Remoxipride.Approved, Withdrawn
ReserpineThe serum concentration of Midazolam can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Midazolam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Midazolam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Midazolam can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Midazolam.Approved, Investigational
RilpivirineThe serum concentration of Midazolam can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Midazolam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Midazolam is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Midazolam can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Midazolam can be increased when it is combined with Rivaroxaban.Approved
RolapitantThe serum concentration of Midazolam can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Midazolam.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Romifidine.Vet Approved
RopiniroleMidazolam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Midazolam.Approved
RotigotineMidazolam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Midazolam.Approved
S-3304The serum concentration of Midazolam can be increased when it is combined with S-3304.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Midazolam.Approved, Vet Approved
SaquinavirThe serum concentration of Midazolam can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Midazolam can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe serum concentration of Midazolam can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Midazolam.Approved, Vet Approved
SelegilineThe serum concentration of Midazolam can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Midazolam.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Midazolam is combined with Sertindole.Approved, Withdrawn
SertralineThe serum concentration of Midazolam can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Midazolam can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Midazolam.Approved
SiltuximabThe serum concentration of Midazolam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Midazolam can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Midazolam can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Midazolam can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Midazolam can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Midazolam can be increased when it is combined with Sivelestat.Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Midazolam.Approved
SolithromycinThe serum concentration of Midazolam can be increased when it is combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Midazolam.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Midazolam.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Midazolam.Experimental
SpiraprilThe serum concentration of Midazolam can be increased when it is combined with Spirapril.Approved
SpironolactoneThe serum concentration of Midazolam can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Midazolam can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StaurosporineThe serum concentration of Midazolam can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Midazolam can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Midazolam can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Midazolam is combined with Sufentanil.Approved, Investigational
SulfinpyrazoneThe serum concentration of Midazolam can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Midazolam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Midazolam is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Midazolam is combined with Sultopride.Experimental
SumatriptanThe serum concentration of Midazolam can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Midazolam can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantMidazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Midazolam can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Midazolam can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Midazolam.Approved
TandospironeThe risk or severity of adverse effects can be increased when Midazolam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Midazolam is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Midazolam.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Midazolam.Approved
TeduglutideThe serum concentration of Midazolam can be increased when it is combined with Teduglutide.Approved
TelaprevirThe serum concentration of Midazolam can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Midazolam can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Midazolam can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Midazolam.Approved
TemocaprilThe serum concentration of Midazolam can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Midazolam.Approved
TerazosinThe serum concentration of Midazolam can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Midazolam can be increased when it is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Midazolam.Experimental
TesmilifeneThe serum concentration of Midazolam can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Midazolam can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetrodotoxin.Investigational
ThalidomideMidazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Midazolam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Midazolam.Withdrawn
ThiorphanThe serum concentration of Midazolam can be increased when it is combined with Thiorphan.Experimental
ThiotepaThe metabolism of Midazolam can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Midazolam is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Midazolam.Approved
TiclopidineThe metabolism of Midazolam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tilidine.Experimental
TimololThe serum concentration of Timolol can be decreased when it is combined with Midazolam.Approved
TipranavirThe serum concentration of Midazolam can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Midazolam can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Midazolam is combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Midazolam.Approved
TopiramateThe risk or severity of adverse effects can be increased when Midazolam is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Midazolam.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Midazolam.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Midazolam.Approved, Investigational
TrandolaprilThe serum concentration of Midazolam can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Midazolam.Approved
TrazodoneThe serum concentration of Midazolam can be decreased when it is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Midazolam is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Midazolam is combined with Trichloroethylene.Experimental
TrifluoperazineThe serum concentration of Midazolam can be increased when it is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Midazolam is combined with Trifluperidol.Experimental
TriflupromazineThe serum concentration of Midazolam can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Midazolam can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Midazolam can be increased when it is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Triprolidine.Approved
TroleandomycinThe serum concentration of Midazolam can be increased when it is combined with Troleandomycin.Approved
TylosinThe serum concentration of Midazolam can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Midazolam can be increased when it is combined with Ubenimex.Experimental
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Midazolam.Experimental
UlinastatinThe serum concentration of Midazolam can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Midazolam.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Midazolam.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Midazolam is combined with Valproic Acid.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Midazolam.Approved
VelpatasvirThe serum concentration of Velpatasvir can be decreased when it is combined with Midazolam.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Midazolam.Approved
VenlafaxineThe metabolism of Midazolam can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Midazolam is combined with Veralipride.Experimental
VerapamilThe metabolism of Midazolam can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Midazolam is combined with Vigabatrin.Approved
VildagliptinThe serum concentration of Midazolam can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Midazolam.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Midazolam.Approved, Investigational
VinorelbineThe serum concentration of Midazolam can be increased when it is combined with Vinorelbine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Midazolam is combined with Vinyl ether.Experimental
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Midazolam.Approved
VoriconazoleThe metabolism of Midazolam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Midazolam is combined with Vortioxetine.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be decreased when it is combined with Midazolam.Approved
XenonThe risk or severity of adverse effects can be increased when Midazolam is combined with Xenon.Experimental
XimelagatranThe serum concentration of Midazolam can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Midazolam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Midazolam can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZaleplonThe risk or severity of adverse effects can be increased when Midazolam is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Midazolam is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Midazolam.Approved
ZimelidineThe serum concentration of Midazolam can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Midazolam can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Midazolam can be increased when it is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Zolazepam.Vet Approved
ZolpidemMidazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Midazolam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Midazolam is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Midazolam is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Grapefruit juice slows the product's absorption and significantly increases its bioavailability.

References

Synthesis Reference

Madhup K. Dhaon, "Process for the preparation of midazolam." U.S. Patent US6262260, issued August, 1979.

US6262260
General References
  1. Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. [PubMed:6135616]
  2. Isojarvi JI, Tokola RA: Benzodiazepines in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res. 1998 Dec;42 Suppl 1:80-92. [PubMed:10030438]
  3. Garratt JC, Gent JP, Feely M, Haigh JR: Can benzodiazepines be classified by characterising their anticonvulsant tolerance-inducing potential? Eur J Pharmacol. 1988 Jan 5;145(1):75-80. [PubMed:2894998]
  4. Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [PubMed:17287588]
  5. Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328. [PubMed:15089115]
External Links
Human Metabolome Database
HMDB14821
KEGG Drug
D00550
KEGG Compound
C07524
PubChem Compound
4192
PubChem Substance
46507611
ChemSpider
4047
BindingDB
21363
ChEBI
6931
ChEMBL
CHEMBL655
Therapeutic Targets Database
DAP000241
PharmGKB
PA450496
IUPHAR
3342
Guide to Pharmacology
GtP Drug Page
HET
08J
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Midazolam
ATC Codes
N05CD08 — Midazolam
AHFS Codes
  • 28:24.08 — Benzodiazepines
PDB Entries
3u5k / 5te8
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedPreventionDepressive State1
0CompletedTreatmentAnxiety Disease1
0CompletedTreatmentBipolar I Disorder / Bipolar II Disorder / Depression, Bipolar / Major Depressive Disorder (MDD) / Suicidal Ideation1
0Not Yet RecruitingTreatmentSedation, Conscious1
0RecruitingTreatmentCancers / Ketamine / Tiredness1
0RecruitingTreatmentMidazolam Overdose1
1Active Not RecruitingNot AvailableAAT Deficiency / AATD / Alpha-1 Antitrypsin Deficiency / Fibrosis, Liver1
1Active Not RecruitingBasic ScienceNash1
1Active Not RecruitingOtherNeoplasms1
1Active Not RecruitingOtherProstatic Neoplasms1
1Active Not RecruitingTreatmentAdvanced Non-Central Nervous System (CNS) Malignancies1
1Active Not RecruitingTreatmentCancer, Ovarian / Carcinoid tumour of the gastrointestinal tract / Colorectal Cancers / Head and Neck Carcinoma / Islet Cell Tumor / Lung Cancers / Metastatic Cancers / Neuroendocrine Carcinoma of the Skin / Pheochromocytomas / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
1Active Not RecruitingTreatmentEpidermal Growth Factor Receptor Mutations / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1Active Not RecruitingTreatmentInfluenza in Humans1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1Active Not RecruitingTreatmentNeoplasms1
1Active Not RecruitingTreatmentPharmacokinetics / Voriconazole1
1Active Not RecruitingTreatmentTumors1
1CompletedNot AvailableChronic Hepatitis C Infection1
1CompletedNot AvailableHIV-infection/Aids1
1CompletedNot AvailableHealthy Volunteers10
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of ASP015K and Midazolam1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Midazolam1
1CompletedNot AvailablePain, Chronic1
1CompletedNot AvailablePharmacokinetic Interactions1
1CompletedNot AvailableSchizophrenia Patients1
1CompletedNot AvailableTumors, Solid1
1CompletedBasic ScienceAlzheimer's Disease (AD) / Metabolism1
1CompletedBasic ScienceAtopic Dermatitis (AD)1
1CompletedBasic ScienceDiabetes Mellitus (DM) / Glucose Metabolism Disorders / Type 2 Diabetes Mellitus1
1CompletedBasic ScienceDrug Biotransformation / Membrane Transport1
1CompletedBasic ScienceDrug Interactions1
1CompletedBasic ScienceEndometriosis1
1CompletedBasic ScienceGenotype-related Drug Metabolism1
1CompletedBasic ScienceHealthy Adult Subjects and Healthy Elderly Subjects1
1CompletedBasic ScienceHealthy Adult Volunteers1
1CompletedBasic ScienceHealthy Male Volunteers1
1CompletedBasic ScienceHealthy Participants1
1CompletedBasic ScienceHealthy Volunteers15
1CompletedBasic ScienceHealthy Volunteers / Human Immunodeficiency Virus (HIV) Infections1
1CompletedBasic ScienceHealthy Volunteers / Pharmacologic Actions1
1CompletedBasic ScienceModerate to Severe Plaque Psoriasis1
1CompletedBasic SciencePharmacokinetic Assessments in Healthy Volunteers1
1CompletedBasic ScienceRheumatoid Arthritis3
1CompletedBasic ScienceType 2 Diabetes Mellitus1
1CompletedBasic ScienceVA Drug Interactions / VA Drug Interactions [VA Drug Interaction]1
1CompletedDiagnosticCytochrome / Pharmacokinetics1
1CompletedDiagnosticDigestive System Disorders1
1CompletedDiagnosticDrug Interactions1
1CompletedDiagnosticHealthy Volunteers2
1CompletedHealth Services ResearchHealthy Volunteers1
1CompletedOtherDrug Interactions / Healthy Volunteers1
1CompletedOtherHealthy Volunteers2
1CompletedTreatmentAcute Myocardial Infarction (AMI) / Pain1
1CompletedTreatmentAdult Solid Neoplasm1
1CompletedTreatmentAdvanced Solid Tumors, Excluding Breast Cancer1
1CompletedTreatmentAmnesia-Memory Loss / Memory Losses1
1CompletedTreatmentAnemias / Healthy Volunteers1
1CompletedTreatmentAtherosclerosis1
1CompletedTreatmentCancers1
1CompletedTreatmentCarcinoma NOS / Hodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Neoplasms / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentCastration Resistant Prostate Cancer (CRPC) / Pharmacokinetics of MDV31001
1CompletedTreatmentCrohn's Disease (CD)1
1CompletedTreatmentDepressive Disorders / Healthy Volunteers1
1CompletedTreatmentDrug Interaction Potentiation1
1CompletedTreatmentDrug Interactions2
1CompletedTreatmentHealthy Male Volunteers1
1CompletedTreatmentHealthy Volunteers23
1CompletedTreatmentHeart Failure, Unspecified1
1CompletedTreatmentHepatitis C, Chronic1
1CompletedTreatmentInfections, Bacterial / Pneumonia / Skin Diseases, Infectious1
1CompletedTreatmentInfectious Diseases1
1CompletedTreatmentJapanese Healthy Adult Males1
1CompletedTreatmentLow Back Pain (LBP)1
1CompletedTreatmentPostmenopausal Osteoporosis (PMO)1
1CompletedTreatmentProphylaxis against postoperative nausea and vomiting / Prophylaxis of acute chemotherapy induced nausea and vomiting1
1CompletedTreatmentPsoriasis2
1CompletedTreatmentRelapsed or Refractory Advanced Cancer1
1CompletedTreatmentSchizophrenia or Schizoaffective Disorder1
1CompletedTreatmentSeizures1
1CompletedTreatmentSkin Diseases, Bacterial1
1CompletedTreatmentTuberculosis1
1CompletedTreatmentTuberculosis / Tuberculosis, Pulmonary1
1CompletedTreatmentTumors, Solid2
1CompletedTreatmentType 2 Diabetes Mellitus2
1CompletedTreatmentCMET-dysregulated Advanced Solid Tumors1
1Not Yet RecruitingTreatmentDrug Interaction Potential1
1Not Yet RecruitingTreatmentHealthy Volunteers / Psoriasis1
1Not Yet RecruitingTreatmentImpaired Renal Function1
1RecruitingBasic ScienceNeoplasms Metastasis1
1RecruitingOtherALK-positive Advanced Tumors1
1RecruitingOtherAdvanced Solid Tumors1
1RecruitingOtherDepression, Bipolar / Major Depressive Episode / Unipolar Depression1
1RecruitingOtherDepressive State / Major Depressive Disorder (MDD) / Recurrent Depressive Disorder / Relapses1
1RecruitingOtherHealthy Volunteers2
1RecruitingOtherLeukemia, Lymphocytic, Chronic, B-Cell1
1RecruitingTreatmentAmyotrophic Lateral Sclerosis (ALS)1
1RecruitingTreatmentCancer, Advanced / Colorectal Cancers / Metastatic Melanoma / Metastatic Non-Small Cell Lung Cancer / Metastatic Pancreatic Ductal Adenocarcinoma1
1RecruitingTreatmentCancer, Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC) / Mesothelioma, Malignant / Metastatic Breast Cancer (MBC) / Metastatic Cancers / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentDRUG REACTIONS1
1RecruitingTreatmentDrug Interaction Potentiation1
1RecruitingTreatmentHealthy Volunteers1
1RecruitingTreatmentHepatitis B,Chronic1
1RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL) / Non-Hodgkin's Lymphoma, Solid Cancers / Solid Cancers1
1RecruitingTreatmentTuberculosis / Tuberculosis, Pulmonary1
1TerminatedBasic ScienceCancer, Advanced1
1TerminatedOtherHealthy Volunteers2
1TerminatedOtherPsoriasis Vulgaris1
1TerminatedTreatmentCervical Pain1
1TerminatedTreatmentEpilepsies1
1TerminatedTreatmentHealthy Volunteers1
1Unknown StatusBasic ScienceHealthy Volunteers1
1Unknown StatusTreatmentHealthy Volunteers1
1WithdrawnTreatmentHealthy Volunteers2
1, 2Active Not RecruitingTreatmentBipolar Disorder (BD) / Major Depressive Episode / Suicidal Ideation1
1, 2CompletedPreventionPost Operative Pain1
1, 2CompletedTreatmentShock, Septic1
1, 2TerminatedPreventionSepsis1
1, 2TerminatedTreatmentDependence, Cocaine1
1, 2TerminatedTreatmentObsessive Compulsive Disorder (OCD)1
2Active Not RecruitingTreatmentObsessive-Compulsive Disorder (OCD)1
2CompletedSupportive CareChildren1
2CompletedSupportive CareDental Anxiety1
2CompletedTreatmentChildren Requiring Sedation to Facilitate Laceration Repair1
2CompletedTreatmentEndoscopy / Procedural Sedation1
2CompletedTreatmentMajor Depressive Disorder (MDD) / Treatment Resistant Depression (TRD)1
2CompletedTreatmentPain1
2CompletedTreatmentSeizures1
2CompletedTreatmentTreatment Resistant Depression (TRD)1
2Not Yet RecruitingPreventionSedation During Spinal Anesthesia1
2Not Yet RecruitingTreatmentMajor Depressive Episode1
2RecruitingDiagnosticDelayed Recovery From Anaesthesia1
2RecruitingPreventionForearm Surgeries1
2RecruitingSupportive CareCancer of Breast / Cancer, Breast / Malignant Neoplasm of Female Breast1
2RecruitingTreatmentBipolar Disorder (BD)1
2RecruitingTreatmentMajor Depressive Disorder (MDD)1
2RecruitingTreatmentMajor depressive disorder, recurrent episode1
2RecruitingTreatmentObsessive-Compulsive Disorder (OCD)1
2RecruitingTreatmentPosttraumatic Stress Disorders1
2RecruitingTreatmentSubarachnoid Haemorrhage (SAH)1
2TerminatedTreatmentFeeling Anxious / Pain1
2Unknown StatusPreventionAdenoidectomy / Otorhinolaryngologic Surgical Procedures / Postoperative Care / Postoperative pain / Surgical Procedures, Operative / Tonsillectomy1
2Unknown StatusSupportive CareIntracranial Hemorrhages / Ischemia, Brain / Strokes / Vasospasm, Intracranial1
2Unknown StatusTreatmentAnxiety Disorders / Depressive State / PTSD / Stress Disorders, Post-Traumatic1
2Unknown StatusTreatmentPost Dural Puncture Headache1
2WithdrawnDiagnosticComputerized tomography / Procedural Sedation / Traumatic Brain Injury (TBI)1
2WithdrawnSupportive CareDelirium / Dyspnea / Nausea / Pain Intractable1
2, 3CompletedPreventionDiagnostic Esophagogastroduodenoscopy1
2, 3CompletedTreatmentAnaesthesia therapy1
2, 3CompletedTreatmentAnalgesia, Patient-Controlled / Spinal Stenosis1
2, 3CompletedTreatmentChronic Otitis Media1
2, 3CompletedTreatmentColonoscopy / Colorectal Polyps1
2, 3CompletedTreatmentCritical Illness1
2, 3CompletedTreatmentDental Anxiety / Impacted Third Molar Tooth1
2, 3CompletedTreatmentSedation therapy1
2, 3Not Yet RecruitingTreatmentAcute Ischemic Stroke (AIS)1
2, 3RecruitingTreatmentFeeling Anxious / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
2, 3RecruitingTreatmentMajor depressive disorder, recurrent episode1
2, 3RecruitingTreatmentPosttraumatic Stress Disorder (PTSD)1
2, 3WithdrawnTreatmentPTSD1
3CompletedNot AvailableChronic Renal Failure (CRF) / Hip Fractures1
3CompletedDiagnosticCancer, Breast1
3CompletedPreventionHypertensive1
3CompletedPreventionPost-operative Pain for Total Knee Arthroplasty1
3CompletedSupportive CareColonoscopy1
3CompletedSupportive CareEpilepsies / Hydrocephaly1
3CompletedTreatmentAcute Traumatic Pain1
3CompletedTreatmentAnaesthesia therapy1
3CompletedTreatmentBronchoscopy1
3CompletedTreatmentChild's Anxiety / Parental/Caregiver Anxiety1
3CompletedTreatmentColonoscopy1
3CompletedTreatmentContinuous Sedation in Initially Sedated Adults in ICU1
3CompletedTreatmentDental Anxiety1
3CompletedTreatmentFracture Bone1
3CompletedTreatmentPaediatric Outpatient Surgery1
3CompletedTreatmentSedation therapy1
3Not Yet RecruitingTreatmentBreech Presentation1
3RecruitingPreventionEmergence Delirium1
3RecruitingSupportive CareFluoride Poisoning / Hepatic Function / Poisoning by Inhaled Anaesthetic / Recovery From Sedation / Renal Function1
3RecruitingTreatmentFeeling Anxious / Peripheral Nerve Blocks1
3RecruitingTreatmentInguinal Hernias / Local Anesthesia / Sedation, Conscious1
3RecruitingTreatmentSedation in Intensive Care1
3RecruitingTreatmentTreatment Resistant Depressive Disorder1
3TerminatedTreatmentAcute Agitated Patients1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentEpilepsies1
3TerminatedTreatmentTraumatic Brain Injury (TBI)1
3Unknown StatusSupportive CareSedation therapy1
3Unknown StatusTreatmentIntubation Complications1
4Active Not RecruitingSupportive CareEpilepsies / Metabolic Diseases / Traumas1
4Active Not RecruitingSupportive CareFeeling Anxious / Laceration1
4Active Not RecruitingTreatmentAcute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Critical Illness / Sleep1
4Active Not RecruitingTreatmentChild Behavior / Dental Decay1
4Active Not RecruitingTreatmentComplications1
4Active Not RecruitingTreatmentDriving Performance After Minor Ambulatory Surgery / Minor Surgical Procedures With Monitored Anesthesia Care1
4CompletedNot AvailableDisorders of Gallbladder, Biliary Tract and Pancrease1
4CompletedNot AvailableFailed Moderate Sedation During Procedure1
4CompletedBasic ScienceAnalgesic Drugs / Antinociceptive Agents1
4CompletedBasic SciencePharmacokinetics1
4CompletedBasic ScienceRejection, Transplant1
4CompletedDiagnosticAlteration of Cognitive Function / Gastrointestinal Dysfunction1
4CompletedPreventionAdrenocortical Deficiency / Hemodynamics Instability1
4CompletedPreventionChronic Diseases1
4CompletedPreventionCognitive Impairments1
4CompletedPreventionDelirium1
4CompletedPreventionDelirium on Emergence / Inhalational Anesthetics Adverse Reaction / Strabismus Following Ocular Surgery1
4CompletedPreventionElective Orthopedic Surgery1
4CompletedPreventionEmergence Agitation1
4CompletedPreventionPatients Undergoing Puncture of the Bone Marrow1
4CompletedSupportive CareAnesthesia; Reaction1
4CompletedSupportive CareEndoscopy1
4CompletedSupportive CareHypothermia1
4CompletedSupportive CareIBS / Malignant Neoplasm of Colon / Polyps1
4CompletedSupportive CareIntubation; Difficult1
4CompletedTreatmentAbscesses / Pain1
4CompletedTreatmentAcute Respiratory Distress Syndrome (ARDS)1
4CompletedTreatmentAggressive Behavior / Depressive State / Feeling Anxious / Postoperative Period / Tiredness1
4CompletedTreatmentAnaesthesia / Premedication1
4CompletedTreatmentBrain Diseases1
4CompletedTreatmentBronchoscopy1
4CompletedTreatmentCataracts / Phacoemulsification1
4CompletedTreatmentChild Behavior / Conscious Sedation Failure During Procedure / Dental Decay1
4CompletedTreatmentCholangiocarcinomas / Choledocholithiasis / Malignant Neoplasm of Pancreas / Pancreatitis1
4CompletedTreatmentColonoscopy / Sedation, Conscious1
4CompletedTreatmentConscious Sedation Failure During Procedure1
4CompletedTreatmentDiagnostic Colonoscopy Screening1
4CompletedTreatmentDrug Safety / Procedural Sedation1
4CompletedTreatmentEarly Childhood Caries1
4CompletedTreatmentEfficacy and Safety of Mivacurium Chloride for Pediatric Patients1
4CompletedTreatmentEndoscopy1
4CompletedTreatmentEndoscopy, Gastrointestinal / Moderate Sedation / Propofol / Target Controlled Infusion (TCI)1
4CompletedTreatmentEndoscopy / Inflammatory Bowel Diseases (IBD) / Sedation therapy1
4CompletedTreatmentEndoscopy / Sedation therapy1
4CompletedTreatmentFailed Moderate Sedation During Procedure1
4CompletedTreatmentFailed Moderate Sedation During Procedure / Minimally Conscious State1
4CompletedTreatmentFeeling Anxious3
4CompletedTreatmentFeeling Anxious / Hepatitis, Chronic / Liver Cirrhosis1
4CompletedTreatmentFeeling Anxious / Laceration1
4CompletedTreatmentFeeling Anxious / Nausea / Pain1
4CompletedTreatmentCaudal epidural block therapy / Forearm Injuries / Orthopedic Procedures / Traumas / Upper Extremity1
4CompletedTreatmentGastrointestinal Stroma Tumors / Lung Cancer Non-Small Cell Cancer (NSCLC) / Renal-cell Cancer1
4CompletedTreatmentHealthy Volunteers / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHernia1
4CompletedTreatmentInadequate or Impaired Respiratory Function / Pain1
4CompletedTreatmentIntraoperative Analgesic Use / Postcraniotomy Headache / Postoperative Analgesic Use / Postoperative Complications1
4CompletedTreatmentKetamine Induced Agitation1
4CompletedTreatmentLung Cancers1
4CompletedTreatmentComputerized tomography / MRI of liver / Ultrasound1
4CompletedTreatmentMajor Depressive Disorder (MDD)1
4CompletedTreatmentMajor Depressive Disorder (MDD) / Suicidal Ideation1
4CompletedTreatmentMechanically Ventilated and Intubated Subjects1
4CompletedTreatmentOther Surgical Procedures1
4CompletedTreatmentOxidative Stress / Sedation therapy1
4CompletedTreatmentProcedural Sedation1
4CompletedTreatmentSedation therapy2
4CompletedTreatmentSedation, Conscious1
4CompletedTreatmentSepsis / Shock, Septic / Systemic Inflammatory Response Syndrome (SIRS)1
4CompletedTreatmentSleep Quality of Patients Undergoing TURP1
4CompletedTreatmentSuicidal Ideation1
4CompletedTreatmentSynovitis of osteoarthritis1
4Enrolling by InvitationTreatmentAnesthesia Complication / Hemodynamics Instability / Ileus paralytic / Nausea / Postoperative pain / Vomiting1
4Enrolling by InvitationTreatmentComplications / Delirium / Ventilations, Mechanical1
4Not Yet RecruitingNot AvailableChildren / Dormicum / Sedation, Conscious1
4Not Yet RecruitingOtherLumbar Punctures / Minor Incision Drainage of Abscesses Not Requiring Extensive Debridement / Sedation, Conscious / Simple Lacerations Less Than 4 cm1
4Not Yet RecruitingPreventionC.Surgical Procedure; Cardiac / Delirium1
4Not Yet RecruitingPreventionCritical Illness1
4Not Yet RecruitingSupportive CareInfertilities1
4Not Yet RecruitingTreatmentAcute Pulmonary Edema1
4Not Yet RecruitingTreatmentCrohn's Disease (CD) / Ulcerative Colitis (UC)1
4Not Yet RecruitingTreatmentPreanesthetic Medication1
4Not Yet RecruitingTreatmentSafety and Efficacy of Intranasal Dexmedetomidine1
4Not Yet RecruitingTreatmentShock, Septic1
4RecruitingBasic ScienceSevere Sepsis1
4RecruitingBasic ScienceType 2 Diabetes Mellitus1
4RecruitingDiagnosticLiver Diseases1
4RecruitingHealth Services ResearchGeneral Surgery / Sedation therapy1
4RecruitingTreatmentAcute Agitation, Behavioural Emergency1
4RecruitingTreatmentAnxiety Disorders / Major Depressive Disorder (MDD)1
4RecruitingTreatmentBladder Tumors / Postoperative Cognitive Dysfunction1
4RecruitingTreatmentCoronary Artery Disease1
4RecruitingTreatmentCritical Illness / Deep Sedation / Ventilators, Mechanical1
4RecruitingTreatmentDexmedetomidine / Mechanically Ventilated Sedated Patients / Midazolam / Sedation therapy / Ventilations, Mechanical1
4RecruitingTreatmentFeeling Anxious / Pediatric ALL / Procedural anxiety1
4RecruitingTreatmentFlexible Bronchoscopy / Safety / Satisfaction / Sedation therapy1
4RecruitingTreatmentKnee Injuries1
4RecruitingTreatmentProstate Cancer1
4RecruitingTreatmentSedation in Intensive Care Unit Patients1
4RecruitingTreatmentSedation therapy1
4RecruitingTreatmentSeizures1
4RecruitingTreatmentTerminal Cancer1
4SuspendedTreatmentPatients Requiring Diagnostic Gastroscopy Suitable for Sedation / Patients Requiring Diagnostic Gastroscopy With Sedation1
4TerminatedTreatmentAnaesthesia therapy1
4TerminatedTreatmentFeeling Anxious1
4TerminatedTreatmentOrthopedic Procedures / Procedural Sedation / Regional Anesthesia Block1
4Unknown StatusNot AvailableObesity, Morbid1
4Unknown StatusBasic ScienceHyperalgesia4
4Unknown StatusPreventionAnaesthetic Preconditioning / Myocardial Injury1
4Unknown StatusPreventionDelirium1
4Unknown StatusPreventionSedative Withdrawal Delirium1
4Unknown StatusTreatmentAnaesthesia therapy / Hemodynamics / Oxidative Stress1
4Unknown StatusTreatmentAnalgesia, Patient-Controlled / Arthroplasty / Gastric Resection1
4Unknown StatusTreatmentCongenital Choledochal Cyst / Congenital Hydronephrosis / Fracture Bone1
4Unknown StatusTreatmentConscious Sedation Failure During Procedure1
4Unknown StatusTreatmentCritical Illness / Ventilations, Mechanical1
4Unknown StatusTreatmentDelirium1
4Unknown StatusTreatmentDexmedetomidine / Mechanically Ventilated Patients / Midazolam / Sedation therapy1
4Unknown StatusTreatmentEmergency1
4Unknown StatusTreatmentFailed Conscious Sedation During Procedure1
4Unknown StatusTreatmentHepatic Encephalopathy1
4Unknown StatusTreatmentInflammatory Disorder of Immune System / Sepsis1
4Unknown StatusTreatmentLaceration1
4Unknown StatusTreatmentLaryngoscopy / Preanesthetic Medication1
4Unknown StatusTreatmentLiver Cirrhosis1
4Unknown StatusTreatmentMechanical Ventilation Complication1
4Unknown StatusTreatmentSafety of Dexmedetomidine Sedation1
4Unknown StatusTreatmentTraumatic Brain Injury (TBI)2
4Unknown StatusTreatmentAdjunct to general anesthesia therapy1
4WithdrawnSupportive CareAlcoholism / Respiration, Artificial1
4WithdrawnTreatmentPostoperative pain1
4WithdrawnTreatmentSleep1
Not AvailableActive Not RecruitingNot AvailableAortic Valve Stenosis1
Not AvailableActive Not RecruitingNot AvailablePostoperative Cognitive Dysfunction1
Not AvailableCompletedNot AvailableAnaesthesia therapy1
Not AvailableCompletedNot AvailableClinical Indications for Transesophageal Echocardiography1
Not AvailableCompletedNot AvailableEarly Gastric Cancer / Gastric Adenoma1
Not AvailableCompletedNot AvailableFeeling Anxious / Satisfaction / Sedation therapy / Tolerance1
Not AvailableCompletedNot AvailablePain1
Not AvailableCompletedNot AvailableRhytidoplasty1
Not AvailableCompletedBasic ScienceCritical Care / Deep Sedation / Sedation, Conscious1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic SciencePharmacokinetics1
Not AvailableCompletedBasic ScienceSaccadic Eye Movements1
Not AvailableCompletedDiagnosticConscious Sedation Failure During Procedure1
Not AvailableCompletedDiagnosticEGD Procedure1
Not AvailableCompletedDiagnosticPain1
Not AvailableCompletedDiagnosticSacroiliac Joint Pain / Sympathetically Maintained Pain1
Not AvailableCompletedOtherEndobronchial Ultrasound Guided Transbronchial Needle Aspiration1
Not AvailableCompletedPreventionAkathisia1
Not AvailableCompletedPreventionAnesthesia Morbidity / Children / Delirium on Emergence1
Not AvailableCompletedPreventionGeneral Surgery1
Not AvailableCompletedPreventionGeneral Surgery / Prostate Cancer1
Not AvailableCompletedPreventionPediatric Emergence Agitation and Pain1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableCompletedPreventionPsychomotor Agitation1
Not AvailableCompletedSupportive CareAnaesthesia therapy / Body Temperature Changes1
Not AvailableCompletedSupportive CareCancers1
Not AvailableCompletedSupportive CareChildren1
Not AvailableCompletedSupportive CareFeeling Anxious1
Not AvailableCompletedSupportive CareFeeling Anxious / Pain1
Not AvailableCompletedSupportive CareLiver Cirrhosis1
Not AvailableCompletedSupportive CarePre Operative Anxiety1
Not AvailableCompletedSupportive CareTransient Hypertension1
Not AvailableCompletedTreatmentAnaesthesia therapy1
Not AvailableCompletedTreatmentAnxiety Preoperative / Midazolam Premedication / Premedication1
Not AvailableCompletedTreatmentBasal Cell Carcinoma (BCC) / Feeling Anxious / Skin Cancers / Squamous Cell Carcinoma (SCC)1
Not AvailableCompletedTreatmentChronic Lung Diseases1
Not AvailableCompletedTreatmentCritical Illness1
Not AvailableCompletedTreatmentEchocardiography, Transesophageal1
Not AvailableCompletedTreatmentEndoscopy / Sedation therapy1
Not AvailableCompletedTreatmentFeeling Anxious1
Not AvailableCompletedTreatmentFractures, Compression1
Not AvailableCompletedTreatmentHemodynamics After Spinal Anesthesia1
Not AvailableCompletedTreatmentIntubations1
Not AvailableCompletedTreatmentOther Surgical Procedures1
Not AvailableCompletedTreatmentPostoperative Cognitive Functions1
Not AvailableCompletedTreatmentPsychomotor Agitation1
Not AvailableCompletedTreatmentRespiration Disorders1
Not AvailableCompletedTreatmentSepsis / Shock1
Not AvailableCompletedTreatmentSepsis / Traumas1
Not AvailableNot Yet RecruitingDevice FeasibilitySedation therapy / Spinal Anaesthesia1
Not AvailableNot Yet RecruitingPreventionPeripheral Obliterative Arteriopathy1
Not AvailableNot Yet RecruitingTreatmentBrachial Plexus Block / Shoulder Dislocation1
Not AvailableNot Yet RecruitingTreatmentObesity, Morbid1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableAnaesthesia therapy1
Not AvailableRecruitingNot AvailableCerebral Ischemia-Hypoxia1
Not AvailableRecruitingNot AvailableDepressive State1
Not AvailableRecruitingNot AvailableGliomas1
Not AvailableRecruitingNot AvailablePsychomotor Agitation1
Not AvailableRecruitingBasic ScienceAmnesia / Anaesthesia therapy / Anesthetics / Pain / Sedation, Conscious1
Not AvailableRecruitingDiagnosticVentricular Tachycardia (VT)1
Not AvailableRecruitingHealth Services ResearchSedation therapy1
Not AvailableRecruitingPreventionIntubation; Difficult or Failed1
Not AvailableRecruitingTreatmentAcute Respiratory Failure1
Not AvailableRecruitingTreatmentAnoxic Encephalopathy / Cardiac Arrest / Refractory seizure disorders1
Not AvailableRecruitingTreatmentColonoscopy1
Not AvailableRecruitingTreatmentIntubated Requiring Sedation for Greater Than 48 Hours1
Not AvailableRecruitingTreatmentMajor Depressive Disorder (MDD) / Severe Depression / Treatment Resistant Depression (TRD)1
Not AvailableRecruitingTreatmentPostoperative Pain Control / Wrist Injury1
Not AvailableRecruitingTreatmentStress, Psychological1
Not AvailableRecruitingTreatmentTonsillectomy1
Not AvailableSuspendedTreatmentPaediatric Flexible Bronchoscopy1
Not AvailableTerminatedNot AvailableVesicoureteral Reflux1
Not AvailableTerminatedTreatmentBMI >30 kg/m2 / Sleep Apnea, Obstructive1
Not AvailableTerminatedTreatmentBipolar Disorder (BD)1
Not AvailableTerminatedTreatmentRespiratory Failure1
Not AvailableUnknown StatusNot AvailableChronic Alcoholism1
Not AvailableUnknown StatusNot AvailableFunctional disorders of the biliary tract / Pancreatic Diseases1
Not AvailableUnknown StatusBasic SciencePhobic Disorders1
Not AvailableUnknown StatusPreventionCystoscopy1
Not AvailableUnknown StatusScreeningAnesthesia Recovery Period / Delirium, Dementia, Cognitive Disorders / Mental Competency / Neurobehavioural Manifestation1
Not AvailableUnknown StatusSupportive CareDiverticulosis, Colonic / Malignant Neoplasm of Colon / Rectal Carcinoma1
Not AvailableUnknown StatusSupportive CarePacemaker Implantation / Pain1
Not AvailableUnknown StatusSupportive CareSleeplessness1
Not AvailableUnknown StatusTreatmentAcute Agitation1
Not AvailableUnknown StatusTreatmentAnaesthesia therapy1
Not AvailableUnknown StatusTreatmentBronchoscopy; / Central Airway Stenosis / Interventional; / Noninvasive Positive Pressure Ventilation / Sedation therapy1
Not AvailableUnknown StatusTreatmentLiver Diseases1
Not AvailableWithdrawnNot AvailableTraumas1

Pharmacoeconomics

Manufacturers
  • Apothecon inc div bristol myers squibb
  • App pharmaceuticals llc
  • Astrazeneca pharmaceuticals lp
  • Baxter healthcare corp anesthesia and critical care
  • Baxter healthcare corp anesthesia critical care
  • Bedford laboratories div ben venue laboratories inc
  • Ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • International medicated systems ltd
  • International medication systems ltd
  • Taylor pharmaceuticals
  • Wockhardt ltd
  • Hlr technology
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Paddock laboratories inc
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Hoffmann la roche inc
Packagers
Dosage forms
FormRouteStrength
LiquidIntramuscular; Intravenous1 mg
LiquidIntramuscular; Intravenous5 mg
SolutionBuccal10 mg
SolutionBuccal2.5 mg
SolutionBuccal5 mg
SolutionBuccal7.5 mg
Injection, solutionIntramuscular; Intravenous10 mg/2mL
Injection, solutionIntramuscular; Intravenous2 mg/2mL
Injection, solutionIntravenous.5 mg/mL
Injection, solutionIntravenous1 mg/mL
InjectionIntramuscular; Intravenous1 mg/mL
InjectionIntramuscular; Intravenous10 mg/2mL
InjectionIntramuscular; Intravenous2 mg/2mL
InjectionIntramuscular; Intravenous5 mg/mL
Injection, solutionIntramuscular; Intravenous1 mg/mL
Injection, solutionIntramuscular; Intravenous5 mg/mL
SyrupOral10 mg/5mL
SyrupOral2 mg/mL
SolutionIntramuscular; Intravenous1 mg
SolutionIntramuscular; Intravenous5 mg
Prices
Unit descriptionCostUnit
Midazolam 5 mg/ml3.9USD ml
Midazolam-nacl 2 mg/ml inj2.31USD ml
Midazolam hcl 5 mg/ml vial1.18USD ml
Midazolam-nacl 1 mg/ml inj1.13USD ml
Midazolam hcl 2 mg/ml syrup1.08USD ml
Midazolam 1 mg/ml isecure syr0.73USD ml
Midazolam hcl 1 mg/ml vial0.26USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)159 °CPhysProp
water solubility0.024 mg/mLThorsteinn Loftsson and Dagný Hreinsdóttir, 2006
Predicted Properties
PropertyValueSource
Water Solubility0.00987 mg/mLALOGPS
logP3.89ALOGPS
logP3.33ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)6.57ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area30.18 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity99.43 m3·mol-1ChemAxon
Polarizability32.7 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9724
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.5074
P-glycoprotein inhibitor IInhibitor0.5587
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.7476
CYP450 2C9 substrateNon-substrate0.7366
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7194
CYP450 1A2 substrateInhibitor0.8586
CYP450 2C9 inhibitorInhibitor0.7132
CYP450 2D6 inhibitorNon-inhibitor0.6887
CYP450 2C19 inhibitorInhibitor0.6554
CYP450 3A4 inhibitorNon-inhibitor0.5214
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9001
Ames testNon AMES toxic0.8024
CarcinogenicityNon-carcinogens0.7703
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1488 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9827
hERG inhibition (predictor II)Non-inhibitor0.7379
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-03di-3839000000-42781254e15bcd5b31b6
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0009000000-2411220f611ba30ef225
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0009000000-c724b297ae99edb399d3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004l-0098000000-b57c162c4eeaad9ef111
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0090000000-a3133528f5491f4c9a6b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-05fs-0290000000-ee126555f849ecfff795
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0009000000-4ae622c7b53369b0cfb1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0019000000-00c3c9e2813a454acda1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-002f-0093000000-a8ca99ef6c84536bff07
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0091000000-3edc4aa6f67d99b789a8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0abd-0290000000-aa5e16437618ad2adb86
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05fs-0490000000-a323090224c5b01e3990
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0189000000-6e704a4a2a65211394ab
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0910000000-98021a5812f1663e9397

Taxonomy

Description
This compound belongs to the class of organic compounds known as imidazo[1,5-a][1,4]benzodiazepines. These are compounds containing an imidazole ring and a 1,4-benzodiazepine ring system, both sharing one nitrogen atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
Imidazo[1,5-a][1,4]benzodiazepines
Alternative Parents
Fluorobenzenes / 1,4-diazepines / N-substituted imidazoles / Aryl fluorides / Aryl chlorides / Heteroaromatic compounds / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
Imidazo[1,5-a][1,4]benzodiazepine / Para-diazepine / Fluorobenzene / Halobenzene / Aryl chloride / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Benzenoid / N-substituted imidazole
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
diazepine (CHEBI:6931)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA4
Uniprot ID
P48169
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-4
Molecular Weight
61622.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB1
Uniprot ID
P18505
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-1
Molecular Weight
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-gated chloride ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB3
Uniprot ID
P28472
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-3
Molecular Weight
54115.04 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB2
Uniprot ID
P47870
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-2
Molecular Weight
59149.895 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA6
Uniprot ID
Q16445
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-6
Molecular Weight
51023.69 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG1
Uniprot ID
Q8N1C3
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-1
Molecular Weight
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRG2
Uniprot ID
P18507
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-2
Molecular Weight
54161.78 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG3
Uniprot ID
Q99928
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-3
Molecular Weight
54288.16 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRD
Uniprot ID
O14764
Uniprot Name
Gamma-aminobutyric acid receptor subunit delta
Molecular Weight
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRE
Uniprot ID
P78334
Uniprot Name
Gamma-aminobutyric acid receptor subunit epsilon
Molecular Weight
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the ute...
Gene Name
GABRP
Uniprot ID
O00591
Uniprot Name
Gamma-aminobutyric acid receptor subunit pi
Molecular Weight
50639.735 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA...
Gene Name
GABRR1
Uniprot ID
P24046
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-1
Molecular Weight
55882.91 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA...
Gene Name
GABRR2
Uniprot ID
P28476
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-2
Molecular Weight
54150.41 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRR3
Uniprot ID
A8MPY1
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-3
Molecular Weight
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transmembrane signaling receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRQ
Uniprot ID
Q9UN88
Uniprot Name
Gamma-aminobutyric acid receptor subunit theta
Molecular Weight
72020.875 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Foti RS, Rock DA, Wienkers LC, Wahlstrom JL: Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010 Jun;38(6):981-7. doi: 10.1124/dmd.110.032094. Epub 2010 Mar 4. [PubMed:20203109]
  2. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A: Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab. 2004 Oct;5(5):415-42. [PubMed:15544435]
  5. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91. [PubMed:12124305]
  6. Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22. [PubMed:12433827]
  7. Obach RS, Reed-Hagen AE: Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos. 2002 Jul;30(7):831-7. [PubMed:12065442]
  8. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Patki KC, Von Moltke LL, Greenblatt DJ: In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44. [PubMed:12814972]
  3. Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E: Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth. 1994 Nov;73(5):658-61. [PubMed:7826796]
  4. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA: Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994 Apr 29;47(9):1643-53. [PubMed:8185679]
  3. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D: Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab Dispos. 1996 Sep;24(9):940-7. [PubMed:8886602]
  4. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, Wrighton SA: Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther. 1998 Sep;286(3):1253-9. [PubMed:9732386]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP4B1
Uniprot ID
P13584
Uniprot Name
Cytochrome P450 4B1
Molecular Weight
58990.64 Da
References
  1. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein homodimerization activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A4
Uniprot ID
P22310
Uniprot Name
UDP-glucuronosyltransferase 1-4
Molecular Weight
60024.535 Da
References
  1. Klieber S, Hugla S, Ngo R, Arabeyre-Fabre C, Meunier V, Sadoun F, Fedeli O, Rival M, Bourrie M, Guillou F, Maurel P, Fabre G: Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab Dispos. 2008 May;36(5):851-62. doi: 10.1124/dmd.107.019539. Epub 2008 Feb 6. [PubMed:18256203]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Tassaneeyakul W, Birkett DJ, Miners JO: Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica. 1998 Mar;28(3):293-301. [PubMed:9574817]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764]
  2. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  4. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T: Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol. 1998 Oct 9;358(3):289-94. [PubMed:9822896]
  5. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372]
  6. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  7. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49